NCT04981470终止不适用
A First in Human Study of Feasibility of Baroloop: The Baroloop Study
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 4
- 试验地点
- 1
- 主要终点
- Composite Major Adverse Event (MAE) Rate
研究概览
简要总结
The baroloop Study is a non-randomized, prospective, single-arm, multi center First in Human (FIH) study with the primary objective being the assessment of the safety and feasibility of using the baroloop System in subjects with uncontrollable hypertension. The secondary objective is to document the effect of the baroloop device on the blood pressure and quality of life in subjects with hypertension. Up to 10 subjects will be enrolled in up to 3 sites in Europe.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18 years or older and less than 80 years of age.
- •Persistent office systolic blood pressure (SBP) ≥ 140 mm Hg and diastolic blood pressure (DBP) > 90 mm Hg on antihypertensive medicines on two visits separated by a minimum of four weeks.
- •Mean 24-hour systolic ABPM ≥ 130 mm Hg and mean 24 hour diastolic ABPM ≥ 80 mm Hg conducted after direct observed therapy to confirm that antihypertensive medicines were taken as prescribed during the ABPM measurement.
- •Stable drug regimen of 4 antihypertensive medicines consisting of a renin-angiotensin blocker(ACE) or Angiotensin II Receptor Blocker (ARBs), a calcium channel blocker (CCB), a diuretic and spironolactone for 4 weeks at treatment. If spironolactone is not tolerated, the regimen must include instead the addition of further diuretic therapy with either eplerenone, amiloride, higher-dose thiazide/thiazide-like diuretic or a loop diuretic, or the addition of bisoprolol or doxazosin. If none of these medicines are tolerated, then patients on a 3-drug regimen may be included.
- •The Investigator has confirmed that the patient has already tried and/or is not suitable for treatment with currently CE-marked device-based therapies for resistant hypertension as an alternative to baroloop therapy.
- •Willingness and ability to comply with follow-up requirements.
- •Signed informed consent.
排除标准
- •Any patient in whom access to the vagal nerve is limited by the size of the vagus (a size not compatible with the baroloop cuff).
- •Any patient with a history of injury to the vagus nerve or its branches (e.g., the recurrent laryngeal nerve).
- •Secondary causes of hypertension.
- •Calculated eGFR < 30 mL/min/1.73m
- •Type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus (HbA1c > 10%).
- •One or more episodes of orthostatic hypotension in the past year
- •Requirement for chronic oxygen therapy or mechanical ventilation.
- •Untreated (no CPAP therapy) sleep apnea (AHI > 15)
- •Morbid obesity, defined as Body Mass Index >40 kg/m2 or arm circumference 46 cm.
- •Pacemaker and/or implantable defibrillators.
- •History of transient ischemic accident or cerebrovascular accident during six (6) months prior to screening.
- •Symptomatic carotid artery disease or > 70% occlusion of either carotid artery; any carotid malformation or lesion, a carotid bruit or other abnormal carotid sound.
- •Prior surgery, radiation therapy or scarring in the neck in the region of the carotid artery (e.g., patients with a tracheostomy, extensive thymectomy or thyroid surgery).
- •Limited mobility of the neck secondary to vertebral disease or prior vertebral surgery, including patients who wear a cervical support.
- •History of heart failure (NYHA class III-IV or ejection fraction < 30%), myocardial infarction, unstable angina, coronary bypass or coronary angioplasty during six (6) months prior to screening.
- •Cardiac arrythmias (atrial fibrillation, atrial flutter, etc.) that require anticoagulation or interfere with a consistent measurement of blood pressure.
- •Syncope in the last 6 months.
- •History of bleeding disorders, thrombocytopenia, hemophilia or significant anemia (hemoglobin (Hgb) < 10 gm/dl).
- •Current anticoagulation therapy (excluding antiplatelet therapy with aspirin as a sole therapy).
- •Works night shifts.
- •History of unresolved drug or alcohol use.
- •Active treatment of a psychiatric ailment.
- •Life expectancy of less than 12 months due to other disease.
- •Subject has a condition that, in the opinion of the investigator, precludes participation, including willingness to comply, with all follow-up procedures.
- •Participation in another clinical study for which follow-up is currently on-going.
- •Women who are of child-bearing age or who have the potential to become pregnant
- •Resting heart rate of <40 beats/min for patients on beta blockers or <60 beats/min for all other patients, confirmed at both baseline visits.
- •Baroreflex failure or autonomic neuropathy
- •Symptomatic, uncontrolled bradyarrhythmias
- •Atrioventricular block of any grade
- •Patients who are treated with Pacemaker and/or implantable defibrillators
- •Presence of a vagus stimulator
- •Patients who expect to require magnetic resonance imaging (MRI) of the cervical area
- •Occupational exposure to high levels of non-ionizing radiation that may interfere with therapy
- •Patients with a limited ability to read, understand and execute adjustment procedures (for example, persons suffering from dementia).
- •Likely exposure to diathermy.
研究组 & 干预措施
Investigational Device
Experimental
Subjects implanted with the baroloop device
干预措施: baroloop System (Device)
结局指标
主要结局
Composite Major Adverse Event (MAE) Rate
时间窗: at 6 months post-treatment
The MAE rate is calculated based on the number of participants that either died, were hospitalized for hypertensive crisis after the first titration visit, or experienced any device or procedure-related serious adverse events.
Feasibility - Device Placement and Vagal Nerve Stimulation
时间窗: Day 14 or Day 21 post-implantation
Feasibility was calculated based on the number of participants in whom the baroloop system was successfully placed around a vagal nerve and stimulation of the nerve was possible. Stimulation of the vagus nerve was attempted for the first time after either 14 or 21 days; depending on the healing progress of the participant after the surgery. Therefore, feasibility (ability to place the device and ability to stimulate the nerve after the surgery) was either confirmed after 14 days or 21 days, depending on the healing progress of the participant after the surgery.
次要结局
- Change in Office Blood Pressure(1, 3, 6, 12, 18 and 24 months)
- Change in Antihypertensive Drugs/Dosages(1, 3, 6, 12, 18 and 24 months)
- Change in Blood Pressure(at the time of implantation)
- Change in 24-hour ABPM(1, 3, 6, 12, 18 and 24 months)
- Composite MAE Rate(1, 3, 12, 18 and 24 months)
- Quality of Life Evaluation - Short Form (36) Health Survey(Baseline, 1, 3, 6, 12, 18 and 24 months)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
Innoventric Trillium™ Stent Graft First-in-Human (FIH) StudyTricuspid RegurgitationNCT04289870Innoventric LTD20
招募中
1 期
Study of BM230 in Patients With Advanced Solid TumorsSolid TumorNCT06644300Suzhou Biomissile Pharmaceuticals Co., Ltd.123
已完成
不适用
Vortex - Temporary Percutaneous, Transvalvular Circulatory Support System Feasibility StudyCoronary Artery DiseaseNCT04674111Boston Scientific Corporation5
招募中
不适用
First In Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients With Superficial Femoral Artery Disease and/or Proximal Popliteal Artery DiseasePopliteal Artery StenosisSuperficial Femoral Artery StenosisNCT06410313Medinol Ltd.30
已完成
1 期
First in human clinical study of a novel drug PTC607 to assess effects of food intake and to compare PTC607 levels, when taken as an oral suspension and tablet formulation.Huntington's DiseaseNeurological - Neurodegenerative diseasesHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersACTRN12623000300673CTI Clinical Trial and Consulting Services Australia Pty Ltd.8